Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 2, 2011, Pages 235-242

  Khan, M S ^a,b   El Khouly, F ^a   Davies, P ^a   Toumpanakis, C ^a   Caplin, M E ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ANGIOPEPTIN; INTERFERON; OCTREOTIDE; OCTREOTIDE DOTA; PANCREAS ENZYME; RADIOISOTOPE; SOMATULINE AUTOGEL; UNCLASSIFIED DRUG; YTTRIUM 90;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CARCINOID SYNDROME; CHEMOEMBOLIZATION; CHOLELITHIASIS; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM TUMOR; DRUG DOSE INCREASE; DRUG RELEASE; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDGUT; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; STEATORRHEA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; PEPTIDES, CYCLIC; RETROSPECTIVE STUDIES; SOMATOSTATIN; TIME FACTORS;

EID: 79959373749     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04693.x     Document Type: Article

References (30)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-72.
2. Reubi JC, Kvols L, Krenning E, Lamberts SW,. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990; 39: 78-81. (Pubitemid 20286341)
3. Srirajaskanthan R, Watkins J, Marelli L, Khan K, Caplin ME,. Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology 2009; 89: 308-14.
4. Davis GR, Camp RC, Raskin P, Krejs GJ,. Effect of somatostatin infusion on jejunal water and electrolyte transport in a patient with secretory diarrhea due to malignant carcinoid syndrome. Gastroenterology 1980; 78: 346-9. (Pubitemid 10128406)
5. Dharmsathaphorn K, Sherwin RS, Cataland S, Jaffe B, Dobbins J,. Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med 1980; 92: 68-9. (Pubitemid 10182168)
6. Long RG, Peters JR, Bloom SR, et al. Somatostatin, gastrointestinal peptides, and the carcinoid syndrome. Gut 1981; 22: 549-53. (Pubitemid 11053340)
7. Pless J,. The history of somatostatin analogs. J Endocrinol Invest 2005; 28: 1-4.
8. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-73. (Pubitemid 39004355)
9. Toumpanakis C, Garland J, Marelli L, et al. Long-term results of patients with malignant carcinoid syndrome receiving Octreotide LAR. Aliment Pharmacol Ther 2009; 30: 733-40.
10. Ricci S, Antonuzzo A, Galli L, et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 2000; 11: 1127-30.
11. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17: 600-6. (Pubitemid 29075248)
12. Tomassetti P, Migliori M, Corinaldesi R, Gullo L,. Treatment of gastroenteropancreatic neuroendocrine tumours with Octreotide LAR. Aliment Pharmacol Ther 2000; 14: 557-60. (Pubitemid 30240747)
13. Sassolas G, Khalfallah Y, Chayvialle JA, et al. Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men. J Clin Endocrinol Metab 1989; 68: 239-46. (Pubitemid 19052859)
14. Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689-96. (Pubitemid 46606312)
15. Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996; 39: 279-83. (Pubitemid 26276007)
16. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002; 87: 99-104. (Pubitemid 34084677)
17. Bajetta E, Procopio G, Catena L, et al. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer 2006; 107: 2474-81. (Pubitemid 44748532)
18. Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004; 80: 244-51. (Pubitemid 40187010)
19. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-63.
20. Modlin IM, Pavel M, Kidd M, Gustafsson BI,. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-88.
21. Plockinger U, Wiedenmann B,. Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab 2007; 21: 145-62.
22. Janson ET, Oberg K,. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993; 32: 225-9. (Pubitemid 23188540)
23. Raderer M, Kurtaran A, Scheithauer W, Fiebiger W, Weinlaender G, Oberhuber G,. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Oncology 2001; 60: 141-5. (Pubitemid 32245332)
24. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000; 88: 770-6. (Pubitemid 30091095)
25. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430-8.
26. Oberg K, Alm G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989; 81: 531-5. (Pubitemid 19102223)
27. Di BM, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996; 77: 402-8. (Pubitemid 26023360)
28. Modlin IM, Lye KD, Kidd M,. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-59. (Pubitemid 36173145)
29. Strosberg J, Nasir A, Coppola D, Wick M, Kvols L,. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 2009; 40: 1262-8.
30. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451: 757-62. (Pubitemid 47497934)